KMA and Co.
  • Why
  • Who
  • What
  • Where
  • Case Studies
  • Blog
Select Page
In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines

In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines

by Cassie Arnold | Feb 9, 2021 | Biotech Finance, COVID, Deal making, Investment

If you had an inkling that more money went to vaccine and diagnostic companies in 2020, you were right.  Diagnostics and vaccines have long been the red-headed stepchildren of life sciences investments. Detecting and treating life threatening diseases is the...
Digital Therapeutic Deals Make Steady Progress in 2020

Digital Therapeutic Deals Make Steady Progress in 2020

by Cassie Arnold | Jan 28, 2021 | Biotech Finance, Deal making, Digital Health, Digital Therapeutics, Investment

After starting off 2020 with a 35 percent drop in the number of deals from the previous quarter, digital therapeutic deal-making steadily climbed over the course of 2020 to total 71 deals for the year. With 25 deals in the fourth quarter of 2020, the index was up 44...
Counting Deals Instead of Votes

Counting Deals Instead of Votes

by Cassie Arnold | Nov 10, 2020 | Biotech Finance, Deal making, Digital Health, Digital Therapeutic

Tired from a long week of parsing electoral college votes? How about focusing on digital therapeutic deals for a change of pace? The third quarter brought a record number of digital therapeutic deals with a total of 19. That’s up from 16 in the previous quarter. The...
Tracking Digital Therapeutics

Tracking Digital Therapeutics

by Cassie Arnold | Feb 25, 2020 | Biotech Finance, Digital Health, Digital Therapeutic

When I started following the digital health sector in earnest about ten years ago, I was intrigued with the potential of digital technology to treat disease – the so-called digital therapeutics. Instead, the sector produced an almost infinite variety of activity...
Is an Ad Campaign the Solution or the Problem?

Is an Ad Campaign the Solution or the Problem?

by Cassie Arnold | Mar 10, 2017 | Biotech Finance

Is an Ad Campaign the Solution or the Problem? Recently the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group representing the US pharmaceutical industry, launched an unprecedented image campaign titled “Go Boldly.” The campaign was rolled...

2017: Above Average VC Investment, Maybe a Record for M&A

by Cassie Arnold | Jan 30, 2017 | Biotech Finance

2017: Above Average VC Investment, Maybe a Record for M&A I’m breaking with tradition and publishing my own predictions for the life sciences sector in 2017. I do research like this all the time for clients, but I never put it out under my own name. I’m taking...

Recent Posts

  • In a Time of COVID, Dealmakers Take a Shine to Diagnostics and Vaccines
  • Digital Therapeutic Deals Make Steady Progress in 2020
  • Counting Deals Instead of Votes
  • What’s in a Name II
  • Mask Messaging

Archives

  • February 2021
  • January 2021
  • November 2020
  • August 2020
  • July 2020
  • April 2020
  • February 2020
  • November 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • April 2019
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • March 2018
  • February 2018
  • November 2017
  • May 2017
  • March 2017
  • January 2017
  • September 2016
  • August 2016
  • April 2016
  • March 2016
  • February 2016
  • December 2015
  • October 2015
  • June 2015
  • April 2015
  • March 2015
  • February 2015
  • November 2014
  • October 2014
  • August 2014
  • June 2014

Categories

  • 21st Century Culture
  • Advertising
  • Biotech Finance
  • Branding
  • Communications
  • COVID
  • Deal making
  • Digital Health
  • Digital Therapeutic
  • Digital Therapeutics
  • Gender at Work
  • Investment
  • Modern Work
  • Persuasion
  • Sales
  • Uncategorized
  • Twitter
  • RSS
© 2021 KMA & Company